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Abstract
Background: Recent studies demonstrate that in addition to its modulatory effect on APP
processing, in vivo application of Liver X Receptor agonist T0901317 (T0) to APP transgenic and
non-transgenic mice decreases the level of Aβ42. Moreover, in young Tg2576 mice T0 completely
reversed contextual memory deficits. Compared to other tissues, the regulatory functions of LXRs
in brain remain largely unexplored and our knowledge so far is limited to the cholesterol
transporters and apoE. In this study we applied T0 to APP23 mice for various times and examined
gene and protein expression. We also performed a series of experiments with primary brain cells
derived from wild type and LXR knockout mice subjected to various LXR agonist treatments and
inflammatory stimuli.
Results: We demonstrate an upregulation of genes related to lipid metabolism/transport,
metabolism of xenobiotics and detoxification. Downregulated genes are involved in immune
response and inflammation, cell death and apoptosis. Additional treatment experiments
demonstrated an increase of soluble apolipoproteins E and A-I and a decrease of insoluble Aβ. In
primary LXRwt but not in LXRα-/-β-/- microglia and astrocytes LXR agonists suppressed the
inflammatory response induced by LPS or fibrillar Aβ.
Conclusion: The results show that LXR agonists could alleviate AD pathology by acting on
amyloid deposition and brain inflammation. An increased understanding of the LXR controlled
regulation of Aβ aggregation and clearance systems will lead to the development of more specific
and powerful agonists targeting LXR for the treatment of AD.
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Recent studies have linked cholesterol metabolism and
AD pathogenesis [1-3] but the molecular and physiologi-
cal mechanisms remain elusive. The liver X receptors
(LXRs), LXRα and LXRβ, are transcription factors that con-
trol the expression of genes involved in cholesterol metab-
olism and lipoprotein remodelling [4]. LXRα/β have been
considered drug targets for cardiovascular disease and
recent reports suggest that LXR ligands could also be ther-
apeutic agents for inflammation and diabetes [5-9]. LXRα
and LXRβ are activated by the same ligands but their tissue
distribution differs: LXRα is highly expressed in liver, adi-
pose tissue, and macrophages and moderately in the
brain, while LXRβ is expressed in all tissues examined and
is highly expressed in brain [10]. Compared to other tis-
sues, the regulatory functions of LXRs in brain remain
largely unexplored and our knowledge so far is limited to
the cholesterol transporters and apoE. Remarkably apoE, a
proven risk factor for sporadic AD, is an LXR target gene.
ATP-binding cassette transporter A1 (ABCA1), a major
regulator of cholesterol efflux and generation of high den-
sity lipoproteins (HDL), is one of the most important LXR
targets. It has been demonstrated that if ABCA1 is func-
tionally impaired, poorly lipidated apoA-I in the periph-
ery becomes unstable and is hyper-catabolized [11]. In
brain, ABCA1 is considered essential for regulation of the
internal cycling of cholesterol between glia and neurons.
Recent data suggest that ABCA1 is essential also for apoE
lipidation and for maintaining of its normal CNS concen-
tration. Lack of ABCA1 in mice results in dramatically
decreased CNS levels of apoE and abnormal structure of
poorly lipidated lipoprotein complexes subjected to rapid
degradation [12-16]. Recently we and two other groups
have shown independently that ABCA1 deficiency
increases Aβ deposition in different lines of APP trans-
genic mice accompanied by a substantial decrease in the
level of brain apoE [12,14,16]. Keeping in mind the role
of apoE in amyloid deposition, one explanation for this
phenotype could be that insufficient and poorly lipidated
apoA-I and apoE either decrease Aβ clearance or facilitate
(apoE in particular) Aβ aggregation [12,14,16-18].
ABCA1 expression in neurons and glia, as well as its level
in the whole brain is markedly increased after exposure to
LXR ligands [19-23]. Furthermore, LXR ligands inhibit Aβ
production in vitro [19-21,24,25] probably by affecting
APP processing [20,24,25].
Studies on LXR activation in brain, have focused so far on
APP models at young ages. It has been demonstrated that
the administration of the synthetic LXR ligand T0 for one
week to young pre-depositing APP, as well as wild type
mice, increased the level of ABCA1 and decreased the lev-
els of Aβ40 [21] and Aβ42 [19,21,26]. Moreover, the appli-
cation of T0 for two weeks to Tg2576 completely reversed
the contextual memory deficit in these mice which further
supported the hypothesis that LXR agonists facilitate the
clearance of Aβ [26]. Although it is not clear whether LXR
activation can also prevent plaque formation, most recent
data from the P. Tontonoz laboratory demonstrated that
global deletion of LXRα or LXRβ in APP transgenic mice
results in increased amyloid plaque load [27] which fur-
ther strengthened the idea that LXR signalling and LXR
responsive genes are important determinants of AD
pathogenesis (at least deposition of fibrillar Aβ and its
clearance) [14,21,27]. The present study was undertaken
to reveal gene and protein expression in brain of 6-month
old APP23 mice subjected to T0 treatment for various
times. We also examined the levels of Aβ, and conducted
experiments in isolated primary brain cells to further con-
firm the effects of LXR agonists on Aβ deposition and
inflammatory reactions in mouse brain.
Results
Upregulation of ABCA1 and apolipoproteins in brain of T0 
treated APP23 mice
Previously we have demonstrated that short T0 treatment
decreased the level of soluble Aβ in 3-month old pre-
depositing APP23 mice in correlation with an increased
ABCA1 level [21]. To determine the effect of activated
LXRs on genes involved in the initial stages of Aβ deposi-
tion in older mice we treated 6-month old APP23 animals
with T0 for 25 days (every day at a dose of 50 mg/kg body
weight; control mice received vehicle; n = 5 for both
groups). We specifically chose APP23 mice at an age when
there is an increase in insoluble Aβ peptides, although
actual amyloid plaques are still rare. At the end of the
treatment total RNA was isolated from cortices and hip-
pocampi and gene expression profiles for both groups
were generated using Affymetrix 430A 2.0 mouse gene
chips. The activation status of LXRs was confirmed by the
increased level of ABCA1 mRNA of T0 versus vehicle
treated mice as measured by RT-QPCR (Fig. 1A).
We identified 168 genes with fold change of at least 1.35
and p < 0.05 (t-test) which fall into the following main
categories: Up-regulated – 75 genes coding for: (1) Lipid
metabolism and transport; (2) Metabolism of xenobiotics
and detoxification; (3) Stress response or response to
stimulus; (4) Nuclear proteins and proteins involved in
DNA binding or transcription. Down-regulated were 93
genes coding for: (1) Proteins involved in immune
response and response to stress and inflammation; (2)
Cell death and apoptosis; (3) Serine/threonine and tyro-
sine protein kinases; (4) Nuclear proteins known to par-
ticipate in chromatin binding and remodelling,
transcription and regulation of transcription. The first two
clusters of up- or down-regulated genes are shown in
Table 1. Results from RT-QPCR assays for selected up- andPage 2 of 15
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and demonstrate that the fold change of all verified genes
was statistically significant and validate the results.
A number of genes identified in the arrays as significantly
upregulated participate in the transport and metabolism
of lipids and cholesterol. The up-regulation of LXR target
genes involved in cholesterol efflux and transport such as
ABCA1, Apolipoprotein A-II, Apolipoprotein C-III and
several others was confirmed by RT-QPCR. A comparison
between fold increase found in gene arrays and by RT-
QPCR, as shown on Fig. 1A and 1B, demonstrates a corre-
lation between the two assays. Three LXR target genes
which were not upregulated in the arrays – ABCG1, apoE
and SREBP1c, were also examined by RT-QPCR. As visible
from Fig. 1A and 1B, ABCG1 was not up-regulated and
apoE showed statistically significant but only a small
(20%) increase. The only exception from the otherwise
good overall correlation between the arrays and RT-QPCR
data was the statistically significant (40%) increase in
SREBP1c expression found by RT-QPCR, which was not
surprising given the sensitivity of the method. The up-reg-
ulation of ABCA1 after extended administration of T0 was
1.6 fold as compared to more than 3.5-fold when T0 was
applied for 24 hours (Fig. 1, compare A and D). The same
difference, although to a smaller extent, was observed for
other LXR target genes related to lipid metabolism, such as
SREBP1c, apoE and ABCG1 (Fig. 1A and 1D), altogether
suggesting that adaptive homeostatic mechanisms could
be in place to modulate expression of ABCA1 and other
Verification of array dataFigure 1
Verification of array data. A, B and C. 6-month old APP23 animals were treated with T0 for 25 days at a dose of 50 mg/kg/day (n = 
5); control mice (n = 5) received vehicle and gene expression profiles were generated using Affymetrix 430A 2.0 mouse gene chips. RT-
QPCR for selected up-regulated (A and B) and down-regulated (C) genes from T0-treated and control mice was performed on the 
same total RNA as used for the array assays and the results compared to those from the array experiments. Fold changes observed in 
arrays (white bars) and RT-QPCR (grey bars) for each gene tested are arranged adjacently (± S.E.M.) and were statistically significant (p < 
0.05 using two-tailed Student's t test). D. 6–7 month old APP23 animals were treated for 24 hours with T0 (50 mg/kg body weight, n = 5); 
control mice (n = 5) received vehicle. Total RNA was extracted from homogenized cortices and hippocampi and the expression of 
selected LXR target genes was determined by RT-QPCR.Page 3 of 15
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Table 1: Differential expression of genes in brains of APP23 mice treated with T0 or vehicle. Fold change is expressed as ratio of 
vehicle versus T0 induced expression level, at p < 0.05.
Fold change Gene symbol Gene product/cluster
Up-regulated
Lipid metabolism and transport
4.60 Fabp1 fatty acid binding protein 1, liver
3.40 Acaa1b acetyl-Coenzyme A acyltransferase 1B
2.70 Gc group specific component (transport of vitamin D sterols)
2.27 Apoa2 apolipoprotein A-II
2.27 Apoc1 apolipoprotein C-I
1.75 Abca1 ATP-binding cassette, sub-family A (ABC1), member 1 (3 copies)
1.60 Hmgcs2 3-hydroxy-3-methylglutaryl-Coenzyme A synthase 2
1.59 Apod apolipoprotein D
1.56 Cpt1a carnitine palmitoyltransferase 1a, liver
1.49 Apoc3 apolipoprotein C-III
1.37 Scd1 stearoyl-Coenzyme A desaturase 1
Metabolism of xenobiotics and detoxification
5.45 Cyp3a11 cytochrome P450, family 3, subfamily a, polypeptide 11
2.07 Cyp4a10 cytochrome P450, family 4, subfamily a, polypeptide 10
1.90 Cyp2e1 cytochrome P450, family 2, subfamily e, polypeptide 1
1.85 Cyp2c29 cytochrome P450, family 2, subfamily c, polypeptide 29
1.74 Ugt1a2 UDP glucuronosyltransferase 1 family, polypeptide A2 (3 copies)
1.57 Adh1 alcohol dehydrogenase 1 (class I)
Down-regulated
Immune response and response to stress and inflammation
3.60 Igk-V28 immunoglobulin kappa chain variable 28 (V28)
2.33 Serpina3n serine (or cysteine) peptidase inhibitor, clade A, member 3N
1.93 Ngp neutrophilic granule protein
1.90 Gp49a glycoprotein 49 A /// leukocyte immunoglobulin-like receptor
1.68 Ifitm1 interferon induced transmembrane protein 1
1.63 Tirap toll-interleukin 1 receptor (TIR) domain-containing adaptor protein
1.62 Gbp2 guanylate nucleotide binding protein 2
1.58 Fcgr2b Fc receptor, IgG, low affinity IIb
1.52 Cd74 CD74 antigen (invariant polypeptide of MCH, class II antigen-associated)
1.50 Tnfaip6
1.49 H2-Aa tumor necrosis factor alpha induced protein 6
1.49 Aif1 histocompatibility 2, class II antigen A, alpha
1.46 Gbp4 allograft inflammatory factor 1
1.40 H2-D1 guanylate nucleotide binding protein 4
1.40 Hif3a /// histocompatibility 2, D region locus 1
LOC64109 hypoxia inducible factor 3, alpha subunit /// similar to hypoxia inducible factor 3, alpha subunit
Cell death and apoptosis
2.15 Wwox WW domain-containing oxidoreductase
1.65 Card10 caspase recruitment domain family, member 10
1.58 Hccs holocytochrome c synthetase
1.55 Elmo1 engulfment and cell motility 1, ced-12 homolog (C. elegans)
1.39 Fadd Fas (TNFRSF6)-associated via death domain
1.50 Hccs holocytochrome c synthetase
1.39 Sphk1 sphingosine kinase 1
Molecular Neurodegeneration 2007, 2:20 http://www.molecularneurodegeneration.com/content/2/1/20LXR targets if T0 is applied for 25 days. The up-regulation
of genes related to cholesterol efflux and transport also
suggests that LXR ligands could affect the formation and
the level of HDL-like lipoproteins in brain similarly to
their effect in circulation.
The increased expression levels of several cytochrome
P450 (Cyp450) enzymes and UDP glucoronosyl trans-
ferases, which are membrane microsomal enzymes, indi-
cate an involvement of LXRs in the detoxification
pathways and steroid (androgen and estrogen) metabo-
lism. Some of these genes were previously identified by
gene array assays as LXR targets in the liver and other tis-
sues [28]. Changes in expression levels of transcription
factors and genes involved in splicing and translation
were also observed, suggesting that in APP23 at this age,
LXRs may regulate transcription of genes via indirect
mechanisms.
T0 treatment affects the level of insoluble Aβ in APP23 
mice
Next we examined if the T0-mediated up-regulation of
ABCA1 and apolipoproteins had an effect on the level of
insoluble Aβ. T0 was administered to 6-month old APP23
mice (n = 5), 5 times per week for 4 weeks at a daily dose
of 20 mg/kg body weight; the control group (n = 5)
received vehicle. We decreased the dose of T0 in an
attempt to minimize the liver steatosis which is a well
known side effect of LXR ligands. At the end of the treat-
ment, mRNA was isolated from the cortex and hippocam-
pus of one hemisphere of each mouse and the activation
of LXRs was confirmed by the increased level of ABCA1
mRNA in T0 versus vehicle treated mice (Fig. 2A). Cortices
and hippocampi from the other hemisphere were homog-
enized and soluble and insoluble proteins were extracted,
as before [14]. We were interested in the levels of apoE
mRNA and protein because of its effect on Aβ aggregation
and clearance [29,30] and we also examined the effect of
LXR on apoA-I which was shown previously to affect Aβ
aggregation in vitro [31]. ApoE and apoA-I in the soluble
brain fraction (solApoE and solApo-A-I as determined by
WB) of T0 treated mice were substantially increased: apoE
more than 3 times and apoA-I more than 13-fold com-
pared to their level in the same fraction of vehicle treated
animals (Fig. 2C). In contrast, T0 treatment decreased sig-
nificantly the level of total Aβ (comprising of Aβ40 and
Aβ42) as measured by WB in the insoluble brain fraction
using 6E10 antibody (Fig. 2B), while the level of soluble
Aβ in the same set of samples was not changed (not
shown). The increase in apoE protein level in T0 treated
mice was accompanied by a small but statistically signifi-
cant up-regulation of apoE mRNA (Fig. 1A). In contrast,
whereas apoA-I protein level was increased by 13-fold, the
increase of its mRNA was not statistically significant (1.6-
fold, p < 0.2, Fig. 2A). It should be noted that we found
similar results for ApoA-I on the microarrays: a 1.5-fold
increase in apoA-I mRNA which was not statistically sig-
nificant (p < 0.19, data not shown). In the insoluble frac-
tion of brain homogenates of T0 treated mice there was no
change in the level of apoE and the increase of apoA-I was
not statistically significant (Fig. 2D). Finally, we found
that there was a negative correlation between the levels of
soluble apoE level and insoluble Aβ (Fig. 2E). This is in
accordance with our studies using APP23/ABCA1-/- mice,
where the lack of ABCA1 caused an increase in amyloid
load accompanied by a substantial decrease in soluble
apoE level, with no change in the level of insoluble apoE
[14]. We conclude that LXR activation increases the level
of soluble apolipoproteins in the brain which correlates
negatively to the level of insoluble Aβ.
Cell type specific LXR regulation of apoE in brain
We interpret the increased level of brain apolipoproteins
after T0 treatment as a combined effect of increased apoE
and ABCA1 mRNA levels. The up-regulation of ABCA1
increases cholesterol efflux and consequently the lipida-
tion of brain apoE and apoA-I, thus decreasing their catab-
olism. We were surprised, however, that the apoE mRNA
up-regulation in the brain was rather small, even though
statistically significant (Fig. 2A). One reason for this might
be that LXR regulation is different in different brain areas.
To test this hypothesis we treated 7 month old APP23
mice with T0 at a dose of 50 mg/kg body weight for 24
hours and examined the expression of several LXR target
genes separately in the cortex and hippocampus (Fig. 3A).
We specifically chose genes that have been previously
implicated in the regulation of cholesterol efflux in brain
– ABCA1, apoE and ABCG1. As shown in Fig. 3A, whereas
T0 increased ABCA1 mRNA similarly in the cortex and
hippocampus, apoE mRNA up-regulation was higher in
the cortex than in the hippocampus. We did not find a
corresponding change in apoE protein level in T0 treated
mice as compared to vehicle treated ones (data not
shown). Another reason for the smaller increase of apoE
mRNA after T0 treatment might be that LXR ligands effec-
tively up-regulate apoE mRNA expression only in a subset
of brain cells. To examine this we treated primary astro-
cytic, microglial and neuronal cultures with T0 and exam-
ined ABCA1 and apoE mRNA expression. Fig. 3B shows
that T0 (used at 10 μM concentration in this experiment)
up-regulates ABCA1 expression in all three cell types in a
similar way. To confirm that the observed effect is LXR
dependent, we performed a series of experiments with
wild type cells and cells obtained from LXRα-/-β-/- double
knockout (LXRdko) mice. We found that ABCA1 mRNA
and protein levels were increased only in wild type cells
(Fig. 3B and 3C, wt versus dko) confirming that the effect
is LXR specific. In contrast, the LXR agonist up-regulated
apoE mRNA expression only in astrocytes and microglia
but not in neurons (Fig. 3D). Fig. 3D demonstrates that T0Page 5 of 15
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Extended T0 treatment increases the levels of soluble apoE and apoA-I proteins and decreases insoluble Aβ in APP23 miceFigure 2
Extended T0 treatment increases the levels of soluble apoE and apoA-I proteins and decreases insoluble Aβ in APP23 
mice. APP23 mice (n = 5) were treated by gastric gavage with T0 for 4 weeks at a dose of 20 mg/kg/day and age-matched control mice 
(n = 5) received vehicle. At the end of the treatment one hemisphere was used for total RNA isolation and the other was used for pro-
tein extraction. Soluble brain proteins were extracted with DEA followed by the extraction of the insoluble proteins from the pellet using 
formic acid. A: Expression level of ABCA1, apoE and apoA-I mRNA as determined by RT-QPCR. B: Insoluble Aβtotal in aliquots from the 
insoluble brain fraction was determined by WB using by 6E10 antibody which recognizes both Aβ40 and Aβ42. The level of Aβtotal was nor-
malized to the level of APP full length (APPfl). C: Amounts of soluble apoE and apoA-I were determined by WB of formic acid extracted 
brain homogenates. The bands were quantified and the level of apoE normalized to the level of GAPDH. D: Insoluble apoE and apoA-I 
were determined by WB of formic acid extracted brain homogenate as in C. Values (A, B, C and D) are means ± SEM and represent fold 
of vehicle (two-tailed Student's t test). E. The level of insoluble Aβtotal correlates negatively to the level of soluble apoE (Spearman Non-
parametric correlation analysis).
Molecular Neurodegeneration 2007, 2:20 http://www.molecularneurodegeneration.com/content/2/1/20increased apoE mRNA only in wild type astrocytes, con-
firming that apoE up-regulation was also LXR dependent.
Therefore, whereas LXRs regulate ABCA1 in all brain cell
types, their effect on apoE is cell-type specific which could
explain the relatively small increase of apoE mRNA iso-
lated from a total brain fraction.
LXR agonists inhibit inflammatory response to LPS and 
fibrillar Aβ in microglia and astrocytes
Our gene array data show that some genes related to
immune response and inflammation, especially those
related to the NF-κB cascade – such as Tirap and
Serpina3n were down-regulated in APP23 mice after T0
treatment. In AD, CNS inflammation is a result of local-
ized activation of microglia in areas surrounding the amy-
loid-β plaques and neurofibrillary tangles [32]. In
addition, upon injury astrocytes assume an activated state
associated with the release of inflammatory mediators
[33]. It was shown that LXR ligands inhibit the expression
of inflammatory mediators in peripheral peritoneal mac-
rophages in response to lipopolysaccharide (LPS) stimu-
lation [7]. Because the activation of microglia is believed
Transcriptional regulation of apoE and ABCA1 expression by LXR in brain, glia and neuronsFigure 3
Transcriptional regulation of apoE and ABCA1 expression by LXR in brain, glia and neurons. A: 7-month old APP23 mice 
were treated with 50 mg/kg T0 for 24 hours. Total RNA was extracted separately from cortices and hippocampi and mRNA expression 
of ABCA1, apoE and ABCG1 were determined by RT-QPCR; h-v, (black bars) – vehicle treatment, hippocampi; h-T0, (white bars) – T0 
treatment, hippocampi, c-v (grey bars), vehicle treatment, cortex; c-T0 (hatched bars), T0 treatment, cortex. B, C and D: Primary neu-
rons, astrocytes and microglia were established from wild type (wt) and LXRα-/-β-/- double knockout mice (dko). Cells were treated with 
10 μM T0 for 24 hours and mRNA expression of ABCA1 (B) and apoE (D) measured by RT-QPCR. Values are means ± SEM and repre-
sent fold of vehicle for the corresponding genotype. C: ABCA1 protein level in wild type (wt) and LXRα-/-β-/- (dko) neurons was deter-
mined by WB. The level of ABCA1 was normalized to the level of GAPDH, and presented (means ± SEM) as fold of vehicle of the 
corresponding genotype in the graph bellow.Page 7 of 15
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flammatory and cytotoxic factors, including nitric oxide
(NO) and IL-1β, we examined the anti-inflammatory
effect of LXR ligands in vitro using microglia and astrocytes
stimulated with LPS and Aβ. Fig. 4A demonstrates that
GW-3965 (GW) (another widely used synthetic LXR ago-
nist), used at 5 μM concentration down-regulated mRNA
expression of the pro-inflammatory genes IL-1β, IL-6 and
iNOS in the microglial cell line BV2. To examine if the
decrease in mRNA expression is LXR dependent we used
primary astrocytes derived from wild type and LXRdko
mice. As visible from Fig. 4B and 4C, GW inhibited LPS
induced up-regulation of iNOS and IL-6 mRNA in wild
type but not in dko astrocytes confirming that the down-
regulation was LXR dependent. Moreover, there was a sta-
tistically significant difference in the expression level of
iNOS and IL-6 between GW-treated wild type and dko
cells (p < 0.01; compare LPS+GW in wt versus LPS+GW in
dko in Fig. 4B and 4C).
Next, we examined if LXR ligands decrease the secretion of
proinflammatory cytokines in primary rat microglial cells
treated with LPS or fibrillar Aβ25–35 and Aβ42 peptides.
First, we examined the effect of T0 on nitric oxide (NO)
production and iNOS protein level which are normally
increased in response to LPS. As shown on Fig. 5A and 5B,
T0 applied 18 hr prior to and then co-applied with LPS
down-regulated the expression of iNOS and NO produc-
tion in rat microglia in a concentration-dependent man-
ner. Similarly, T0 (used at 10 μM concentration) inhibited
the expression of iNOS in Aβ treated cells and production
of NO in the conditioned media (Fig. 5C and 5D). Notice-
ably, T0 decreases iNOS protein even bellow its basal level
(p < 0.01, vehicle versus Aβ25–35+T0 in Fig. 5D).
Because the results of our experiments shown on Fig. 4
demonstrate downregulation of the inflammatory
cytokines IL-1β and IL-6 mRNA, we also examined the
effect of LXR ligands on their secretion induced by LPS or
fibrillar Aβ. As visible from Fig. 6A LPS increased the secre-
tion of IL-1β more than 5 fold and T0 suppressed this
effect in a dose-dependent manner. The basal secretion of
IL-6 in these cells was undetectable but LPS and aggre-
gated Aβ induced it to a measurable level with Aβ having
a smaller effect. Again, the application of either of the two
LXR ligands – T0 or GW (used at 5 μM), decreased the pro-
duction of IL-6 from these cells.
T0 treatment decreases the expression of pro-
inflammatory genes in APP23 mice
To examine further the effect of LXR ligands on brain
inflammation we used APP23 mice at age of 7 moths. At
this age there is a substantial increase of aggregated Aβ in
their brain paralleled by inflammatory reactions [34]. We
applied T0 (50 mg/kg/day) to mice randomized in two
separate groups (n = 5 for both): the mice in the first
group were treated with T0 for 24 hours and those in the
second for 25 days every day. At the end, the expression of
several pro-inflammatory genes was measured by RT-
LXR agonists down-regulate expression of pro-inflammatory genes in microglia and astrocytesFigure 4
LXR agonists down-regulate expression of pro-inflamma-
tory genes in microglia and astrocytes. Microglial cell line 
BV2 and astrocytes established from wild type (wt) and LXRdko 
(dko) mice were pre-treated with LXR ligand GW or vehicle for 
18 h prior to LPS treatment (50 ng/ml). Control cells received 
vehicle only (veh). For GW treated cells (LPS+GW) the ligand was 
co-applied with LPS. Cells were harvested 24 hours after LPS 
administration and the mRNA expression measured by RT-QPCR. 
A: BV-2 cells. Values are fold of vehicle. *, p < 0.05 LPS+GW 
treated compared to LPS only treated cells. B and C: WT and 
dko astrocytes were treated with LPS and GW as in A and mRNA 
expression of iNOS (B) and IL-6 (C) measured by RT-QPCR. Val-
ues (means ± SEM) are fold of wild type, vehicle treated cells of at 
least two independent experiments. Note that unlike in WT cells, 
GW does not decrease the expression of iNOS and IL-6 in dko 
cells. (LPS+GW in dko versus LPS+GW in WT, p < 0.01). For all 
experiments, LXR ligands were applied at 5 μM concentration. 
Statistics were performed by two-tailed Student's t test.Page 8 of 15
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APP23 mice did not affect the expression of the examined
pro-inflammatory genes. In contrast, extended T0 treat-
ment of APP23 mice decreased significantly mRNA
expression of IL-1β, IL-6 and TNFα. The expression of
iNOS and COX2 showed a trend towards a decrease
although the difference was not significant (Fig. 7B). We
conclude that LXR ligands decrease the expression of cer-
tain pro-inflammatory genes induced by amyloid deposits
in vivo only if administered for a longer period of time. At
present, it is unclear if LXR ligands directly suppress the
transcription of these genes or the effect is indirect.
Discussion
Epidemiological, clinical and experimental studies have
suggested a link between cholesterol metabolism and AD
pathogenesis [35-41]. Despite the therapeutic potential of
this link, the mechanisms by which cholesterol metabo-
lism influences AD pathogenesis are still unclear. LXR tar-
get genes control the removal of excess cholesterol
through efflux, catabolism or decreased absorption, lipid
metabolism and lipoprotein remodelling [4]. Because of
their regulatory effect on different aspects of lipid metab-
olism it has been speculated that LXR ligands might
impact metabolic disease and atherosclerosis particularly.
We have reported that a short treatment, 6 days, of young
APP23 transgenic mice with the synthetic LXR ligand T0
T0 down-regulates LPS- and Aβ – induced iNOS synthesis and NO production in primary rat microgliaFigure 5
T0 down-regulates LPS- and Aβ – induced iNOS synthesis and NO production in primary rat microglia. Rat microglia was 
pre-treated with increasing concentration of T0 (LPS+T0) or vehicle (LPS only) prior to the addition of LPS (100 ng/ml) and the ligand 
was co-applied with LPS. Control cells received vehicle only (veh). Cells were harvested 24 hours after LPS administration and the 
expression of iNOS was examined by WB. A and B: Concentration dependent effect of T0 on LPS-induced iNOS protein and NO pro-
duction in primary rat microglia. Microglia was pre-treated with increasing concentration of T0 (LPS+T0) or vehicle (LPS only) prior to 
the addition of LPS (100 ng/ml) and the ligand was co-applied with LPS. Control cells received vehicle only (veh). Cells were harvested 24 
after LPS treatment and the expression of iNOS was examined by WB (A). NO in the conditioned media was measured by Griess rea-
gent (B). C and D: T0 (10 μM) inhibits NO production (C) and iNOS protein (D) induced by fibrillar Aβ25–35 or Aβ42 peptides applied 
for 24 hours to microglia. Note that T0 decreases iNOS even bellow its basal level if applied with Aβ (in D, veh versus Aβ25–35+T0, p < 
0.01). Values are means ± SEM; two-tailed Student's t test; *, p < 0.05.Page 9 of 15
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[21]. Using another APP transgenic model (Tg2576) or
WT mice and applying T0 for up to 14 days, two other
groups found a decrease in Aβ42 but not in Aβ40 levels
[19,42]. At the age of treatment, the mice used in the sec-
ond study were pre-deposing, i.e. lacking insoluble Aβ,
and therefore the observed effect was a result of a
decreased level of soluble Aβ peptides.
In the present study we wanted to determine which genes
are affected on the expression level by extended T0 treat-
ment and if the administration of T0 to APP23 mice
decreases amyloid deposition at the age when plaque for-
mation begins. Our results show that prolonged adminis-
tration of T0 at 50 mg/kg/day in APP23 mice up-regulated
T0 decreases the expression of pro-inflammatory genes in APP23 micFigure 7
T0 decreases the expression of pro-inflammatory genes 
in APP23 mice. 7 month old APP23 mice (n = 5) were treated 
by gastric gavage with T0 at a dose of 50 mg/kg/day for 24 hours 
(A) or 4 weeks (B), 6 times a week and age-matched control mice 
(n = 5) received vehicle. At the end of the treatment total RNA 
was isolated from cortices and hippocampi and mRNA expression 
of indicated genes determined by RT-QPCR. Values are means ± 
SEM and represent fold of change compared to vehicle treatment 
(two-tailed Student's t test).
LXR ligands decrease the secretion of pro-inflammatory cytok nes in primary rat microgl al cells treated with LPS or fibrillar Aβ25–35Figure 6
LXR ligands decrease the secretion of pro-inflammatory 
cytokines in primary rat microglial cells treated with LPS 
or fibrillar Aβ25–35. A: Rat microglia were treated with increas-
ing concentrations of T0 and LPS as in Fig. 5 and IL1-β secretion 
measured by ELISA. B and C: Rat microglia were treated with 5 μM T0 and GW and then LPS (B) or Aβ25–35 (C) as in Fig. 5; IL-6 
secretion was measured by ELISA. The values (means ± SEM) indi-
cate the concentration of the cytokines in mg/ml and are normal-
ized to the total cellular protein (TP). LXR treatments are 
compared to LPS or Aβ25–35 alone by two-tailed Student's t test.*, 
p < 0.05, **, p < 0.01, and ***, p < 0.001.Page 10 of 15
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A previous study exploring transcriptional profiling of T0
treated non-APP transgenic mice identified some of these
genes as differentially up-regulated in the brain of LXRwt
but not in LXRdko mice [28]. In terms of AD phenotype, we
observed that T0 mediated activation of LXR increased
protein level of soluble apoE and apoA-I in the brain
which correlated negatively to the level of insoluble Aβ.
This is in agreement with our previous studies in APP/
ABCA1-/- mice where the elevation of amyloid load was
accompanied by considerable decrease of soluble brain
apoE [14]. At the same time the magnitude of the increase
of apoE protein did not correspond to the rather small
increase of apoE mRNA as identified in gene arrays, and
by RT-QPCR. One reason for this is that apoE is selectively
up-regulated in different brain cell types – in glia but not
in neurons. Similarly, in peripheral cells apoE is transcrip-
tionally regulated by LXR in macrophages and adipocytes
but not in liver cells [43]. We speculate that the increased
protein level of apoE following T0 treatment is a combi-
nation of: (1) LXR mediated transcriptional up-regulation
of apoE and (2) transcriptional up-regulation of ABCA1 in
glia that leads to an increased cholesterol efflux. The net
effect is an increased level of properly lipidated brain
apoE.
In brain the lipidation of apoA-I, which comes primarily
from the circulation, depends on ABCA1, as it does in the
periphery and similarly to the mechanism for apoE lipida-
tion, which has been extensively discussed in relation to
Aβ deposition and clearance [2,12,14,16]. There are no
published data that LXRα/β exert a regulatory role on
apoA-I expression at the transcriptional level in mouse or
human cells and cell lines, although, such a regulatory
mechanism has been demonstrated in chick embryo
hondrocytes [44]. Nevertheless, T0 administered to
APP23 mice causes an increase in apoA-I transcript (albeit
not statistically significant) and protein. The results from
our study allow an explanation, based on the so-called
antagonizing effect of T0 on NF-κB, which results in
down-regulation of NF-κB responsive genes [7]. It has
been shown that cytokines exert a strong inhibitory effect
on apoA-I expression at the mRNA and protein levels in
both human and mouse primary cells, established cell
lines, and in vivo [45,46]. Our Affymetrix gene array and
RT-QPCR assays clearly demonstrate that a prolonged
application of T0 to APP23 mice ultimately causes a
decrease in TNFα and IL-6 expression levels. While ABCA1
upregulation and ABCA1-facilitated cholesterol efflux are
the primary mechanisms for apoA-I lipidation and its
increased stability, we consider the sustained inhibition of
cytokines as one additional mechanism for elevated
expression of apoA-I and thus an increased amount of sol-
uble apoA-I in brain.
Properly lipidated and therefore stable apoE and apoA-I,
are an indispensable part of functional HDL-like lipopro-
tein complexes in brain. The legitimacy of this hypothesis
is confirmed by the studies demonstrating that LXR ago-
nist treatment of mice increases plasma levels of HDL,
HDL particle size and apoA-I protein [47] – effects attrib-
uted to the increased ABCA1 expression and cholesterol
efflux. In brain the increased expression of ABCA1 could
lead to: (1) an increase in the amount of Aβ bound to
lipid-rich apoE, which may have a significant role in
maintaining the level of soluble Aβ and preventing it from
aggregation, and (2) an increased delivery of Aβ to astro-
cytes for degradation, or Aβ clearance through the blood
brain barrier. Support for this hypothesis is provided by a
recent study [27], which revealed an increased plaque
load in APP transgenic mice with global deletion of LXRα
or LXRβ, and further reinforced the idea that LXRs and
their responsive genes are important determinants in AD
pathogenesis [2,14,20].
Our results from gene array assays demonstrated that a
number of genes related to immune response and inflam-
mation were down-regulated in the brain of APP23 mice.
This group of genes was not identified previously [28] as
differentially affected by T0 in LXRwt or LXRdko probably
because the animals in that study were not APP expressing
transgenic mice. In the course of AD, CNS inflammation
is an invariant finding and is considered a result of a local-
ized activation of microglia by fibrillar or oligomeric Aβ.
AD brain with active chronic neurodegeneration is
primed to elicit faster and more pronounced proinflam-
matory responses to central and systemic inflammatory
challenges. The up-regulation of inflammatory genes
identified by microarray in incipient AD supports such a
notion [48]. Moreover, a recent study demonstrated that
with aging, without any neurodegenerative pathology,
there was an up-regulation in immune/inflammatory
pathways [49]. Different protein markers including MHC
class I and class II proteins, IgG Fc-gamma receptors, pro-
inflammatory cytokines and tumor necrosis factor alpha
(TNF-α) were found upregulated in AD and some of those
were down-regulated by LXR ligand in our gene array
assays. Similar data have been recently published by Zel-
cer et al [27]. Using primary glia, the authors demon-
strated up-regulation of proinflammatory genes in
response to fibrillar Aβ and a strong inhibitory effect of
GW. In their study expression profiling of GW treated BV2
cells revealed up- or down-regulation of genes clustered in
two groups primarily related to lipid metabolism and
transport, while LPS treatment of the cells strongly
induced a battery of inflammatory genes, which were
potently repressed if GW was added to the culture.
In our study, Serpina3n is a gene that was down-regulated
(more than 2-fold, Fig. 1C) after extended T0 treatment ofPage 11 of 15
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tion. Serpina3n is a murine homolog of human α-Anti-
chymotrypsin and is one of 13 closely related inhibitors
within the murine serpina3 cluster [50]. In brain, α-Anti-
chymotrypsin is a component of the acute inflammatory
response. Human α-Antichymotrypsin has been identi-
fied in amyloid plaques and was shown to promote Aβ
aggregation as well as tau phosphorylation [51-53]. In this
study we also demonstrate that LXR ligands have anti-
inflammatory effect in primary microglia and astrocytes
activated by LPS or fibrillar Aβ. Most importantly we
found that T0 inhibits the expression of pro-inflammatory
cytokines in the brain of APP23 mice after extended but
not short-term (24 hours) application.
Conclusion
Many observations substantiate the hypothesis that the
presence of activated microglia in vulnerable areas of AD
brains accelerates the undergoing pathological processes
presumably triggered by soluble and fibrillar Aβ aggre-
gates and deposits. It is becoming increasingly evident
that LXR controlled genes are involved in many steps of
AD pathogenesis, which makes LXRs promising therapeu-
tic targets in AD. An increased understanding of the LXR
controlled regulation of Aβ aggregation and clearance sys-
tems will lead to the development of more specific and
powerful agonists targeting LXR for the treatment of AD.
Methods
Chemicals
T0901317 was obtained from Cayman Chemicals (Ann
Arbor, Michigan). The following were purchased from
Sigma (Saint Louis, MO): LXR ligand GW-3965 (GW),
lipopolysaccharide (LPS) from Salmonella typhimurium,
delipidated calf serum, leupeptin, aprotinin, and 4-(2-
aminoethyl)benzenesulfonyl fluoride hydrochloride
(AEBSF). Aβ1–42 and Aβ25–35 peptides were purchased
from Bachem (King of Prussia, PA). Tissue culture flasks
and plates were from Corning (Corning, NY) and Falcon
(Lincoln, NJ). In stock solutions T0 and GW were dis-
solved in ethanol at a 1,000-fold final concentration. The
source of all cell culture reagents, if unspecified, was Inv-
itrogen (Carlsbad, CA).
Aβ peptides and aggregation conditions
Aβ1–42 and Aβ25–35 peptides were dissolved in H2O to a
concentration of 250 mM. Fibrillar Aβ were generated by
incubating 250 μM of different Aβ peptides for 6 days
with shaking at 37°C, as previously described [31] and
additionally diluted in culture medium to the desired
final concentration before addition to the cell culture.
Fibril formation was monitored by Thioflavine-T fluores-
cence and Congo red measurements [31].
Antibodies
Rabbit polyclonal anti-ABCA1 antibody was purchased
from Novus (Littleton, CO). The 6E10 monoclonal anti-
body (Signet, Dedham, MA) recognizes the first 17 amino
acids of the Aβ peptide. This antibody was used for West-
ern blotting (WB) of total Aβ and to detect full-length
human APP and sAPPα. Rabbit C8 polyclonal antibody
[21] was used to detect CTF resulting from α – or β-secre-
tase cleavages. Rabbit 869 antibody [21] was used to
detect sAPPβ by WB. Murine-specific polyclonal apoE
antibody was from Santa Cruz (Santa Cruz, CA), polyclo-
nal murine-specific anti-apoA-I antibody was from Rock-
land Immunochemicals, Inc. (Gilbertsville, PA), anti-
inducible nitric oxide synthase (iNOS) monoclonal anti-
body was from BD Biosciences (San Jose, CA) and Glycer-
aldehyde-3-phosphate dehydrogenase monoclonal
antibody was purchased from Chemicon International
(Temecula, CA). The following antibodies were used for
ELISA: (1) Aβ – anti-Aβ40 (G2–10 mAb) and anti-Aβ42
(G2–13 mAb) monoclonal antibodies conjugated to
horseradish peroxidase were from Genetics Company
(Schlieren, Switzerland); (2) capture and detection anti-
bodies for IL-1β were from Biosource International Inc.,
(Camarillo, CA). ELISA kit (Duoset) for IL-6 was from
R&D Systems, Inc (Minneapolis, MN). Secondary anti-
bodies conjugated to horseradish peroxidase were from
Jackson ImmunoResearch (West Grove, PA).
Transgenic mice
The study fully conformed to the guidelines outlined in
the Guide for the Care and Use of Laboratory Animals
from the U.S. Department of Health and Human Services
and was approved by the University of Pittsburgh Institu-
tional Animal Care and Use Committee. We used APP23
transgenic mice (C57BL/6 background) expressing
human familial AD mutant APP751 with Swedish double
mutation at positions 670/671 (APPK670N, M671L). The
expression of human APPsw is driven by the murine Thy-
1 promoter and is restricted to neurons [54].
In vivo treatments
5–7 month old APP23 mice were treated by gastric gavage
with T0 dissolved in propylene glycol/Tween 80 (4/1) as
in [21] for: (1) 25 days with 50 mg/kg/day (n = 5); (2) 5
times per week for 4 weeks at a dose of 20 mg/kg/day (n =
5); (3) 50 mg/kg for 24 hours (n = 5). Control mice (n =
5 for each treatment group) received vehicle. It is well
known that T0 treatment increases the level of triglycer-
ides in the liver causing steatosis. We measured liver
weight (T0 versus veh) after completion of each T0 treat-
ment as a criterion for steatosis. 24 hours treatment didn't
increase the liver weight. 50 mg/kg/day of T0 applied for
25 days increased liver weight in treated animals by 84%
and 20 mg/kg/day for 30 days by 40% (all data, relative to
vehicle treated animals.)Page 12 of 15
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Mice were asphyxiated with CO2 and perfused transcar-
dially with 30 ml PBS (0.1 M, pH 7.4). Brains were rapidly
removed, the olfactory bulb and cerebellum deleted, and
hemibrains were snap-frozen on dry ice. Where indicated,
cortices and hippocampi were dissected and processed
separately.
RNA isolation and Affymetrix gene array assay
Total RNA from homogenized cortices and hippocampi
was isolated using TRIzol reagent according to the manu-
facturers protocol (Invitrogen) with ethanol precipitation
and a second clean-up using Qiagen RNeasy mini kit. The
integrity of the RNA samples was assessed qualitatively on
Agilent 2100 Bioanalyzer to assure high quality (ratios for
28S to 18S bands close to 2:1) of total RNA. One Cycle
cDNA synthesis Kit (Affymetrix) was used for first and sec-
ond strand cDNA synthesis. Cleanup, and synthesis of
biotin-labelled cRNA for target labelling assays was
accomplished by GeneChip IVT labelling kit (Affymetrix).
Following cleanup and quantitation, cRNA was frag-
mented for target hybridization and probe arrays were
hybridized for 16 hours. Washing and staining were auto-
matically performed on Fluidics Station 450 and the
arrays were scanned on GeneChip® Scanner 3000. All sub-
sequent statistical analyses have been performed on orig-
inal CEL files containing raw probe intensity data for each
array using Array Assist software (Stratagene, CA). Func-
tional annotation clustering analysis was performed using
DAVID Bioinformatics Resources 2007 (National Insti-
tute of Allergy and Infectious Diseases, NIH).
Real Time Quantitative PCR
Total RNA from brain tissue was isolated and purified as
described for gene array assays. For TaqMan® based RT-
QPCR first-strand cDNA was synthesized using Sprint™
PowerScript™ PrePrimed Single Shots (Clontech). All Taq-
Man® gene expression assays were performed using ready
to use probe and primer sets for the corresponding genes
on ABI 7500 Real-Time PCR System (Applied Biosys-
tems). Amplification plots were analyzed by Comparative
ΔCt method with mouse GAPDH or cyclophilin as house-
keeping genes [55]. Primer sequences are available upon
request.
Protein extraction, Western blotting and ELISA
To extract proteins, brains (150 mg/ml buffer) were
homogenized in Tris/sucrose buffer (250 mM sucrose, 20
mM Tris base, 1 mM EDTA, 1 mM EGTA, pH 7.4) using a
glass vessel and piston-type Teflon pestle as previously
described [2,56]. Protein extracts were prepared: (1) RIPA
– 1:1 dilution of the initial homogenate with RIPA buffer
(10 mM Tris-HCl, pH 7.3, 1 mM MgCl2, and 0.25% SDS,
1% Triton X-100) in the presence of protease inhibitors
(10 μg/ml leupeptin, 10 μg/ml aprotinin and 10 μg/ml
AEBSF), sonicated and used for Western blotting (WB) for
ABCA1 and full length APP as before (cit); (2) soluble and
insoluble brain proteins (Aβ and apolipoproteins) were
extracted essentially as described previously [2,56].
Briefly, soluble proteins were extracted using cold 0.4%
diethylamine in 100 mM NaCl, spun at 135,000 × g for 1
h at 4°C, and neutralized by adding 0.5 M Tris-HCl, pH
6.8. The pellet was further extracted using 70% cold for-
mic acid, sonicated for 1 min, spun as above, and neutral-
ized (1 M Tris base, 0.5 M Na2HPO4, and 0.05% NaN3).
WB for insoluble Aβ was performed using 10 μl of formic
acid extracted Aβ. The solvent (formic acid) was evapo-
rated and the pellet resuspended in 2 × NUPAGE loading
buffer. The proteins were resolved on 4–12% Bis Tris
NUPAGE gels and transferred on the nitrocellulose mem-
branes. Membranes were boiled for 5 min in PBS and Aβto-
tal was detected with 1:1000 dilution of 6E10 antibody.
Soluble Ab was measured in RIPA extracted fraction by
WB using 6E10. Soluble Ab was also measured in diethyl-
amine extracted protein fraction by ELISA performed
using 6E10 as the capture antibody and anti-Aβ40 (G2–10
mAb) and anti-Aβ42 (G2–13 mAb) monoclonal antibod-
ies conjugated to horseradish peroxidase as detection anti-
bodies. The amount of Aβ was normalized either to the
total protein or to the expression of APPfl as measured by
WB. To detect soluble apoA-I and apoE we used diethyl-
amine extracted protein fraction. WB for insoluble pro-
teins was performed as before [2], using 10 μl of formic
acid extracted insoluble fraction as described above for
Aβ. 10% Tris-Glycine gels were used to resolve soluble and
insoluble apoA-I and apoE.
Primary cell culture
All primary cells were obtained from dissociated cortices
and hippocampi. Primary neurons were derived from
17–18-day-old wild type or LXRdko mouse embryos as
described previously [20]. Briefly, cells were derived from
cortices and hippocampi (dissociated with 1× trypsin-
EDTA for 10 min at room temperature) and cultivated in
Neurobasal medium supplemented with B27, GlutaMax
II (Invitrogen) and antibiotics. Neurons were plated at
high density (2 × 105/ml, 1 ml/well) on poly-D-lysine
(100 μg/ml) coated 12 well Costar plates and used at Day
in Vitro 5. Primary mouse (C57BL/6J) and rat microglial
cells were derived from newborn mouse or rat pups
respectively using the same protocol and essentially as
before. Astrocytes were derived from newborn pups of
wild type or LXRα-/-β-/- and used for few passages. Micro-
glia and astrocytes were cultivated in DMEM with 10%
FBS. Protein expression level of ABCA1 and apoE was
measured by WB in RIPA extracted cell lysates using the
respective antibodies.Page 13 of 15
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The experiments were performed essentially as before
[7,57]. Briefly, cells (in DMEM with 5% delipidated
serum) were pre-treated with LXR ligands 18 hours prior
LPS or Aβ treatment and then the ligands were co-applied
with LPS or Aβ. Cells were treated 24 hours with LPS (50
ng/ml) or Aβ (50 μM). The protein expression level of
iNOS was measured in the cell lysate by WB. Nitric oxide
production was measured in the conditioned media using
Griess assay [7]. The secretion of IL-1β and IL-6 was exam-
ined in the conditioned media using mouse ELISA kits
from Biosource and R&D respectively as suggested by the
manufacturer.
Statistical analysis
Results are reported as mean ± SEM. Statistical signifi-
cance was determined by two-tailed Student's t test. We
used Spearman correlations to determine the unadjusted
relationships between continuous variables (GraphPad
Prism software, Windows version 4.0, San Diego, CA).
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